- Home
- CURR vs AGEN Comparison
CURR vs AGEN Comparison
Compare CURR & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURR
- AGEN
- Stock Information
- Founded
- CURR 2013
- AGEN 1994
- Country
- CURR Singapore
- AGEN United States
- Employees
- CURR N/A
- AGEN N/A
- Industry
- CURR Business Services
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CURR Consumer Discretionary
- AGEN Health Care
- Exchange
- CURR Nasdaq
- AGEN Nasdaq
- Market Cap
- CURR 151.4M
- AGEN 142.8M
- IPO Year
- CURR N/A
- AGEN 2000
- Fundamental
- Price
- CURR $1.60
- AGEN $4.52
- Analyst Decision
- CURR Strong Buy
- AGEN Buy
- Analyst Count
- CURR 1
- AGEN 2
- Target Price
- CURR $3.50
- AGEN $14.50
- AVG Volume (30 Days)
- CURR 162.0K
- AGEN 390.1K
- Earning Date
- CURR 08-04-2025
- AGEN 11-11-2025
- Dividend Yield
- CURR N/A
- AGEN N/A
- EPS Growth
- CURR N/A
- AGEN N/A
- EPS
- CURR N/A
- AGEN N/A
- Revenue
- CURR $41,092,419.00
- AGEN $101,706,000.00
- Revenue This Year
- CURR N/A
- AGEN $26.25
- Revenue Next Year
- CURR $14.56
- AGEN N/A
- P/E Ratio
- CURR N/A
- AGEN N/A
- Revenue Growth
- CURR N/A
- AGEN N/A
- 52 Week Low
- CURR $0.33
- AGEN $1.38
- 52 Week High
- CURR $7.08
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- CURR 50.53
- AGEN 47.27
- Support Level
- CURR N/A
- AGEN $4.36
- Resistance Level
- CURR $1.71
- AGEN $5.20
- Average True Range (ATR)
- CURR 0.12
- AGEN 0.27
- MACD
- CURR -0.08
- AGEN 0.05
- Stochastic Oscillator
- CURR 88.61
- AGEN 38.20
About CURR Currenc Group Inc. Ordinary Shares
Currenc Group Inc is a fintech pioneer dedicated to transforming financial services through artificial intelligence (AI). It empowers financial institutions with comprehensive AI solutions, including the SEAMLESS AI Call Centre and other AI-powered tools designed to reduce costs, increase efficiency, and boost customer satisfaction. The Company's digital remittance platform also enables e-wallets, remittance companies, and corporations to provide real-time, 24/7 payment services, advancing financial access across underserved communities. It generates the majority of its geographic revenue from Malaysia.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).